R

Radiopharm Theranostics Ltd
NASDAQ:RADX

Watchlist Manager
Radiopharm Theranostics Ltd
NASDAQ:RADX
Watchlist
Price: 4.93 USD -2.38% Market Closed
Market Cap: $11.5B

Operating Margin

-929%
Current
Improving
by 5 892.8%
vs 3-y average of -6 821.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-929%
=
Operating Income
AU$-33.8m
/
Revenue
AU$3.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-929%
=
Operating Income
$-33.8m
/
Revenue
AU$3.6m

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Radiopharm Theranostics Ltd
ASX:RAD
66.7m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Lower than 74% of companies in Australia
Percentile
26th
Based on 3 951 companies
26th percentile
-929%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Radiopharm Theranostics Ltd
Glance View

Market Cap
11.5B USD
Industry
Biotechnology

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is a developer of platform of radiopharmaceutical products for both diagnostic and therapeutic uses. The company has a pipeline of four licensed platform technologies, namely Nano- monoclonal antibodies (mAbs) technology, Pivalate, AVb6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its clinical program includes five Phase I clinical trials, five Phase II clinical trials, and two Phase I clinical trials targeting a various cancer, including breast, lung, kidney, head and neck, pancreatic and brain. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, and RAD201 among others.

RADX Intrinsic Value
37.63 USD
Undervaluation 87%
Intrinsic Value
Price
R
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-929%
=
Operating Income
AU$-33.8m
/
Revenue
AU$3.6m
What is Radiopharm Theranostics Ltd's current Operating Margin?

The current Operating Margin for Radiopharm Theranostics Ltd is -929%, which is above its 3-year median of -6 821.7%.

How has Operating Margin changed over time?

Over the last 2 years, Radiopharm Theranostics Ltd’s Operating Margin has increased from -11 706.5% to -929%. During this period, it reached a low of -12 407.6% on Jun 30, 2024 and a high of -929% on Jul 30, 2025.

Back to Top